News

06.11.2017

“We want to improve the visibility of startups at the University of Basel”

“We want to improve the visibility of startups at the University of Basel”

Christian Elias Schneider has been Head of Innovation at the University of Basel for eight months now. His job is to promote entrepreneurship and projects in collaboration with industry.

mehr >
16.11.2017

Myovant Sciences increases research expenses

The Basel-based pharmaceutical company Myovant Sciences reduced its net loss in the second quarter by just under five million dollars compared to the previous year. It significantly increased its research and development expenses.

mehr >
15.11.2017

Basel attracts international professionals

Basel, copyright: Andreas Zimmermann

Basel – Basel is the most attractive city in Switzerland for professionals from abroad. In the latest Expat City Ranking, Basel came ahead of both Zurich and Geneva and ranks among the top 10 in the world.

mehr >
03.10.2017

"You should always have something crazy cooking on the back burner"

When Jennifer Doudna gave her keynote at Basel Life in September, the auditorium in the Congress Center was packed. Susan Gasser, Professor of Molecular Biology at the University of Basel introduced Doudna as groundbreaking and extremely innovative. The Professor of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley was on top of Gassers wish list for the Basel Life. The leading figure of what is known as the CRISPR revolution among scientists sat down with BaselArea.swiss during her stay in Basel to talk about her lab, flexible career paths and what makes a great researcher.

mehr >
13.11.2017

Novartis presents current state of research

Novartis presents current state of research

Novartis presented recent developments in its research programme to investors in London, including positive results for its ophthalmology treatment RTH258.

mehr >
10.11.2017

Myovant drug performs well in study

Basel – The Basel-based pharmaceutical company Myovant Sciences has announced positive results from a study evaluating relugolix. The drug performed well in efficacy and safety for the treatment of uterine fibroids.

mehr >
29.09.2017

Spirochem opens new state-­of-­the-­art Services and R&D facilities in Basel

Spirochem opens new state-­of-­the-­art Services and R&D facilities in Basel

Basel – The fine chemicals company SpiroChem has relocated to state-of-the-art facilities in the Rosental area of Basel, offering the company an ideal location to significantly expand its operations. SpiroChem has also strengthened its board of directors.

mehr >
09.11.2017

Evolva secures further development

Evolva secures further development

The ingredients manufacturer Evolva has secured gross revenue of more than 80 million Swiss francs through the offering of new shares. The company now plans to focus on the commercial success of three products.

mehr >
07.11.2017

Swissbau Innovation Lab: Interaktive Einblicke ins digitale Bauen

Swissbau Innovation Lab: Interaktive Einblicke ins digitale Bauen

Vom 16. bis zum 20. Januar 2018 findet in Basel die Swissbau statt, die grösste Schweizer Baumesse. Dabei spielt die Digitalisierung in der Bauwirtschaft eine tragende Rolle: Die neue Sonderschau Swissbau Innovation Lab macht die Chancen der digitalen Transformation in der Bauwirtschaft erlebbar. Ziel ist es, die Marktteilnehmer besser miteinander zu vernetzen und all jene zusammenzubringen, die am Bauprozess beteiligt sind. Dies erleichtert den Dialog und stärkt Innovationskraft sowie Wettbewerbsfähigkeit. Eine führende Rolle bei der Entwicklung der Inhalte übernimmt die Interessengemeinschaft Bauen digital Schweiz. Darüber hinaus engagiert sich KTI – die Kommission für Technologie und Innovation des Bundes – als Förderer und Katalysator für Innovationen im KMU-Bereich. Die Hochschule für Architektur, Bau und Geomatik FHNW ist Research und Planning Partner des Innovation Lab.

mehr >
18.09.2017

13 startup projects qualify for the first phase of BaseLaunch

13 startup projects qualify for the first phase of BaseLaunch

The BaseLaunch Healthcare Accelerator program from BaselArea.swiss started on September 14. Over 100 applications were received from more than 30 countries, and the selection committee has selected 13 projects to go on to Phase I. Now, the project teams will work with industry experts to further develop their business case over the next three months.

mehr >
07.11.2017

Basel economy confirms positive trends

Basel economy confirms positive trends

Around 80 per cent of companies in Basel rate the current course of business as satisfactory or even good. This positive mood is even more pronounced in the life sciences sector, according to a survey conducted by the Basel Chamber of Commerce.

mehr >
07.11.2017

Austausch unlimited: Grenzüberschreitende Industrie 4.0

«Echtzeit und Industrie 4.0»

Was bedeutet Industrie 4.0 für Unternehmen in Deutschland, Frankreich und in der Schweiz? Wie nehmen Firmen in den drei Ländern die Chancen der Digitalisierung wahr und welche Antworten finden die Beteiligten auf die vielen noch offenen Fragen?

mehr >
05.09.2017

"In Switzerland, we often sell promising technologies too early"

Ulf Claesson is a "serial entrepreneur". During the past 25 years, he has set up companies that have gone on to become firmly established in the market. In 2012, he joined Clinerion as CEO and shareholder. Since then, the company has positioned itself in the medical data field and recently entered into a partnership with British company Cisiv. Clinerion's software helps recruit patients for clinical trials run by major pharmaceutical companies – in real time. But the competition never sleeps. A growing number of competitors is now appearing, especially in the USA where there is no shortage of risk capital. In this interview for the Innovation Report, Claesson explains how the Basel-based healthtech company plans to maintain its leadership position.

mehr >
06.11.2017

NousCom wins over investors

NousCom wins over investors

NousCom, a Basel-based oncology company, raised 42 million euros in a Series B financing round. It will use the new funds to drive development of its lead vaccine candidate, NOUS-209.

mehr >
06.11.2017

L’apport des matériaux hautes performances dans le développement de composants et d’outils industriels innovants

L’apport des matériaux hautes performances dans le développement de composants et d’outils industriels innovants

Le 28 novembre de 11h30 à 13h30, à Courroux, BaselArea.swiss et Creapole SA vous invitent à participer à un événement sur la thématique des matériaux hautes performances. Cette rencontre s’inscrit dans une série de trois événements organisés en Suisse romande dans trois cantons partenaires (JU, NE, VD). Un premier événement a récemment eu lieu au

Y-Parc d’Yverdon lors duquel une trentaine d’industriels étaient présents. Les participants se sont estimés très satisfaits de cette rencontre et les échanges réalisés à l’issue de l’événement ont déjà permis de planifier des rendez-vous individuels.

mehr >
04.07.2017

"I want to turn innovative research into new drugs"

Cellestia CEO Michael Bauer.

Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the NOTCH signal path. There are currently no effective treatments – but this is set to change. Cellestia Biotech AG is developing an innovative drug against this type of cancer by using a novel active ingredient that selectively attacks the malfunctioning cell communication. The drug could be used to treat leukaemia, lymphomas and solid tumours such as breast cancer.

mehr >
03.11.2017

Swiss Innovation Forum: Vom Traum zur innovativen Geschäftsidee

Swiss Innovation Forum: Vom Traum zur innovativen Geschäftsidee

Am 16. November 2017 findet im Congress Center Basel bereits zum zwölften Mal das Swiss Innovation Forum (SIF) statt. Die führende Innovationskonferenz der Schweiz ist eine einzigartige Plattform zur gezielten Förderung von Kreatitivät, Design und Innovation und steht dieses Jahr unter dem Motto «DREAM». Die über 1000 Teilnehmenden sollen träumen, in Gedanken schweben und während einem Tag den Alltag vergessen können. So entsteht Raum für neuartige Denkweisen, kreative Methoden und mutige Designs. Rund 20 Speaker aus dem In- und Ausland zeigen auf, wie aus visionären Träumen innovative Geschäftsideen entstehen.

mehr >
02.11.2017

The first BaselHack convinces with working prototypes

The first BaselHack convinces with working prototypes

Approximately 70 software developers, technology enthusiasts and creative minds met for one of the first hackathons in Basel area at the FHNW Academy of Art and Design (HGK). The so called „BaselHack“ was organized by the association that was founded mid 2017.

mehr >
13.06.2017

Roivant is creating a buzz in Basel

Roivant is creating a buzz in Basel

Roivant Sciences, a fast-growing life sciences company from the US, recently opened its global headquarters in Basel. In celebration of their newly established location, Roivant, together with BaselArea.swiss, invited stakeholders from the life sciences sector to “Halle 7, Gundeldingerfeld” in Basel on June 8th 2017 for a panel discussion on the future of healthcare.

mehr >
02.11.2017

Baloise introduces new preventive technology

Baloise introduces new preventive technology

The Basel-based insurance company Baloise has invested in the U.S startup Insurdata. The aim is to use augmented reality to measure the insurance risks for property more accurately.

mehr >
01.11.2017

Clinerion expands its global coverage

Clinerion expands its global coverage

The Basel-based startup Clinerion is expanding its patient recruit system by adding 60 million patients in North America. A strategic partnership with Provisio also gives Clinerion access to the U.S. company’s data analytics tools.

mehr >
08.06.2017

BaselArea.swiss got off to a successful start

BaselArea.swiss got off to a successful start

In its first annual report, the newly formed BaselArea.swiss can look back on a successful 2016. The joint initiative for innovation and economic promotion by the cantons of Basel-Stadt, Basel-Landschaft and Jura succeeded in growing in all areas. It provided assistance to 36 companies moving to the region, which corresponds to a 50% increase over the previous year. In the area of innovation promotion, over 4,000 participants attended 80 events, expanding the regional network from 8,000 to 13,000 innovators and experts. The services provided by BaselArea.swiss were also actively used to promote start-up projects, contributing to 43 companies being founded.

mehr >
31.10.2017

Solvatec installs prize-winning solar energy system

Solvatec installs prize-winning solar energy system

The photovoltaic façade system from Roche in Kaiseraugst in the canton of Aargau has been awarded the Swiss Solar Prize 2017. Solvatec AG from Basel installed the system.

mehr >
31.10.2017

“Sell Your Science”: Best Practices for Developing an Effective Non-Confidential Pitch Deck

“Sell Your Science”: Best Practices for Developing an Effective Non-Confidential Pitch Deck

It can be tricky to communicate the full potential of your discoveries without spilling the secret sauce. Join Johnson & Johnson Innovation, JLABS for a session on learning the tricks of the trade in preparing a non-confidential deck and executive summary. Experts of the craft will share practical tips on becoming more effective in communicating your story to investors, increasing your chances of successful fundraising. Speakers include:

mehr >
08.06.2017

A molecular assembly line to cure the body

A molecular assembly line to cure the body

Imagine that certain forms of blindness could be cured. Or imagine that the body itself could produce a cure for some of its own diseases. These may be just some of the results of the National Centre of Competence in Research Molecular Systems Engineering (NCCR MSE). Its long-term goals are to create molecular systems and factories for the production of high added-value chemicals and develop cellular systems for new applications in medical diagnostics, therapy and treatment. Director Thomas Ward is aiming high: He wants to make Basel the leading hub for the next European flagship project. At stake: one billion euro.

mehr >
30.10.2017

Novartis to strengthen oncology portfolio with new acquisition

Novartis to strengthen oncology portfolio with new acquisition

The Basel-based pharmaceutical company Novartis has entered into a memorandum of understanding to acquire Advanced Accelerator Applications, a French radiopharmaceutical company that specializes in nuclear medicine. The purchase price amounts to nearly $4 billion.

mehr >
27.10.2017

Scale measures weight of living cells

Scale measures weight of living cells

Researchers in Basel have developed a scale for measuring the weight of living cells, and it is generating significant interest across several fields, including the pharmaceutical sector. The Basel-based company Nanosurf AG is already working to put the device into production.

mehr >
15.05.2017

Investing in strengths – Swiss leadership in life sciences

Investing in strengths – Swiss leadership in life sciences

How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech and Digitization Day, Federal Councillor Johann Schneider-Ammann visited the Basel region to discuss current trends and challenges with a high-ranking delegation from politics, business, research and start-ups.

mehr >
26.10.2017

Oettinger Davidoff commits to Basel

Oettinger Davidoff commits to Basel

The premium cigars manufacturer Oettinger Davidoff opened its new headquarters in Basel on Wednesday. This significant investment in Maison Davidoff marks the company’s commitment to the location.

mehr >
24.10.2017

Basel pharmaceuticals lead the way in research

Basel pharmaceuticals lead the way in research

The two Basel-based pharmaceutical companies Roche and Novartis are the two Swiss companies with the highest spending on R&D. They are also among the top 10 worldwide.

mehr >
09.05.2017

The healthcare system must take responsibility

The healthcare system must take responsibility

Kristian Schneider wants to improve the quality of health care and better manage the rising healthcare costs by means of a network that includes doctors, hospitals, insurance companies and the state. Its aim is to provide exactly those services needed for the health of patients. For the canton of Jura, which like all other cantons suffers from the fragmentation of service providers, this could be a unique opportunity to build an integrative care system – and thus become a pioneer, says the director of Hôpital du Jura.

mehr >
23.10.2017

Roivant enters into partnership with AstraZeneca

Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences

Basel – The pharmaceutical company Roivant Sciences will develop a drug for AstraZeneca, marking the first time the two companies will work together.

mehr >
23.10.2017

Basilea to receive 5 million Swiss francs

Basilea to receive 5 million Swiss francs

The Basel-based biopharmaceutical company Basilea is to receive a milestone payment from Astellas Pharma triggered by strong sales of its anti-fungal medication Cresemba in the U.S.

mehr >
21.04.2017

Basel-Landschaft welcomes new companies

Basel-Landschaft welcomes new companies

The canton of Basel-Landschaft welcomed a host of new companies over the past few weeks. BaselArea.swiss played in a big role in attracting the companies to establish themselves in Basel.

mehr >
19.10.2017

New medicines are driving Roche’s growth

New medicines are driving Roche’s growth

The Basel-based pharmaceutical company Roche increased group sales by 5 per cent in the first nine months of the year. The recently launched medicines Tecentriq, Ocrevus und Alecensa contributed strongly to this growth.

mehr >
18.10.2017

BC Platforms advances multiple sclerosis research

BC Platforms advances multiple sclerosis research

The data management company BC Platforms has announced collaborations with multiple partners to better understand the genetic basis of multiple sclerosis. BC Platforms also intends to build a research platform in Great Britain.

mehr >
12.04.2017

“I see a very innovation-friendly climate in Basel”

“I see a very innovation-friendly climate in Basel”

It all began with research resources that were a quarter of a century old. Simon Ittig and his colleagues at the Biozentrum of the University of Basel turned these into a research project – and eventually a start-up. T3 Pharmaceuticals develops new therapies to treat solid tumours.

mehr >
17.10.2017

The European Antibody Congress opens its doors

The European Antibody Congress opens its doors

Partnered with Basel Area Swiss and the city of Basel, and now in its 13th year, the European Antibody Congress is bringing together 600 delegates, 200 speakers and 70 exhibitors from big pharma, biotechs, clinicians, researchers and innovative start-ups. The Congress takes place during three consecutive days from 31st October to 2nd November 2017 at the Congress Centre in Basel.

mehr >
17.10.2017

Roche invests in novel antibiotics

Roche invests in novel antibiotics

The Basel-based pharmaceutical company Roche is collaborating with the U.S. biotechnology firm Warp Drive Bio, which developed a proprietary technology platform to discover and develop novel classes of antibiotics.

mehr >
05.04.2017

Companies continue to find Switzerland appealing

View over the Rhine river

Bern – More foreign companies relocated to Switzerland last year than in any previous year. Economic development agencies attracted innovative companies with high value creation.

mehr >

 

(Source: http://www.baselarea.swiss/en/baselarea-swiss/channels/innovation-report.html)